Study of REM-422 in Patients With AML or Higher Risk MDS

Conditions: Myelodysplastic Syndromes; Higher Risk Myelodysplastic Syndromes; Acute Myeloid Leukemia; Acute Myeloid Leukemia Refractory Interventions: Drug: REM-422 Sponsors: Remix Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials